The proposed HEOR and Pharmacoeconomics unit includes cost-effectiveness studies, budget impact analysis, real-world evidence and value dossier preparation.
This content can explain how scientific and economic evidence supports clinical, regulatory and market access decisions in Latin America.
Methodologies, templates and deliverables should be adapted to the access objective, population, economic perspective and evidence availability.